Clarke PA - Search Results

1

Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements.

Large JM, Torr JE, Raynaud FI, Clarke PA, Hayes A, Stefano Fd, Urban F, Shuttleworth SJ, Saghir N, Sheldrake P, Workman P, McDonald E. Large JM, et al. Among authors: clarke pa. Bioorg Med Chem. 2011 Jan 15;19(2):836-51. doi: 10.1016/j.bmc.2010.12.006. Epub 2010 Dec 9. Bioorg Med Chem. 2011. PMID: 21216151

2

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I, Workman P. Clarke PA, et al. Oncogene. 2000 Aug 24;19(36):4125-33. doi: 10.1038/sj.onc.1203753. Oncogene. 2000. PMID: 10962573

3

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Hostein I, et al. Among authors: clarke pa. Cancer Res. 2001 May 15;61(10):4003-9. Cancer Res. 2001. PMID: 11358818

4

Innovative cancer drug targets: genomics, transcriptomics and clinomics.

Workman P, Clarke PA. Workman P, et al. Among authors: clarke pa. Expert Opin Pharmacother. 2001 Jun;2(6):911-5. doi: 10.1517/14656566.2.6.911. Expert Opin Pharmacother. 2001. PMID: 11585007 No abstract available.

5

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR. Kelland LR, et al. Among authors: clarke pa. Clin Cancer Res. 2001 Nov;7(11):3544-50. Clin Cancer Res. 2001. PMID: 11705875

6

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

Clarke PA, te Poele R, Wooster R, Workman P. Clarke PA, et al. Biochem Pharmacol. 2001 Nov 15;62(10):1311-36. doi: 10.1016/s0006-2952(01)00785-7. Biochem Pharmacol. 2001. PMID: 11709192 Review.

7

Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides.

Ross PJ, George M, Cunningham D, DiStefano F, Andreyev HJ, Workman P, Clarke PA. Ross PJ, et al. Among authors: clarke pa. Mol Cancer Ther. 2001 Nov;1(1):29-41. Mol Cancer Ther. 2001. PMID: 12467236

8

Assays for HSP90 and inhibitors.

Aherne W, Maloney A, Prodromou C, Rowlands MG, Hardcastle A, Boxall K, Clarke P, Walton MI, Pearl L, Workman P. Aherne W, et al. Methods Mol Med. 2003;85:149-61. doi: 10.1385/1-59259-380-1:149. Methods Mol Med. 2003. PMID: 12710206 Review. No abstract available.

9

Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective.

Maloney A, Clarke PA, Workman P. Maloney A, et al. Among authors: clarke pa. Curr Cancer Drug Targets. 2003 Oct;3(5):331-41. doi: 10.2174/1568009033481822. Curr Cancer Drug Targets. 2003. PMID: 14529385 Review.

10

Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling.

Clarke PA, George ML, Easdale S, Cunningham D, Swift RI, Hill ME, Tait DM, Workman P. Clarke PA, et al. Cancer Res. 2003 Oct 15;63(20):6855-63. Cancer Res. 2003. PMID: 14583483

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters